Overview


Adam W. Burrowbridge focuses his practice on complex intellectual property litigation in district court and the Federal Circuit. He counsels clients in the life science and technology sectors and covers a wide range of technologies, including pharmaceuticals, software, medical devices and consumer products. He has extensive experience representing both plaintiffs and defendants in all phases of litigation, from filing of suit through trial, appeal and practice at the US Supreme Court.

Show More

Results


  • Secured a Federal Circuit reversal of a patent term adjustment decision that cost his clients more than a year and a half of patent term relating to the oral pulmonary hypertension drug Orenitram, invalidating a US Patent and Trademark Office (USPTO) regulation that the Federal Circuit had previously affirmed as reasonable (Supernus et al. v. Iancu)*
  • Secured a Federal Circuit affirmance invalidating two formulation patents relating to Sanofi’s blockbuster insulin glargine Lantus product (Mylan v. Sanofi-Aventis (PTO))*
  • Obtained favorable dismissal of cell sorter patent litigation (Cytonome v. NanoCellect (D. Del.))*

Show More

Recognitions


  • Washington, DC Super Lawyers, Intellectual Property, 2019 to present

Community


  • Federal Circuit Bar Association, member
  • Giles Rich Inn of Court, member
  • Edward Coke Inn of Court, member
  • Washington Council of Lawyers, member

Credentials


Education
American University Washington College of Law, JD, 2011
Integrated Science and Technology, James Madison University, BS, 2003

Courts / Agencies
US Supreme Court
US Court of Appeals for the Federal Circuit
US Court of Appeals for the Sixth Circuit
US Court of Appeals for the Ninth Circuit
US Court of Appeals for the Eleventh Circuit
US Court of Appeals for Veterans Claims

Admissions
District of Columbia
Virginia

Adam W. Burrowbridge

Insights & Events / Media

No results using the selected filter(s)